Symbiotec Pharmalab Ltd. has filed its DRHP with SEBI for a Book Building IPO aggregating up to ?2,180 crore, comprising a fresh issue of ?150 crore and an offer for sale of ?2,030 crore. The company is engaged in the development and manufacturing of APIs, nutritional ingredients and specialty pharmaceutical products, catering to domestic and international regulated markets with strong regulatory compliance and R&D-led manufacturing.
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | -- |
| Non-Institutional Investors (NIIs | 15% | -- |
| Retail Individual Investors (RIIs) | 35% | -- |
Symbiotec Pharmalab Ltd’s total income 0 by 0.00% and total expenses 0 by 0.00%, resulting in an EBITDA 0 by 0.00% and a profit after tax (PAT) 0 by 0.00% between March 31, 2025 and March 31, 2026.
Global leadership in corticosteroid and steroidal-hormone APIs
Strong regulatory approvals including US FDA and EU-GMP
Vertically and backward-integrated manufacturing platform
Long-standing relationships with global pharmaceutical customers
Continuous investment in R&D and innovation
| Allotment Date | Listing Date |
|---|---|
| -- | -- |
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Symbiotec Pharmalab Ltd ipo has been designed to ensure broad participation while maintaining optimal price discovery.
385 / 2 Pigdamber Near Mashal Hotel Indore